The mu 3 opiate receptor subtype is expressed in human surgical specimens of both normal lung and non-small-cell lung carcinoma. Nitric oxide (NO) release is mediated through the mu 3 receptor, and in lung carcinoma, morphine-stimulated NO release is significantly higher and prolonged than in normal lung. Using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis we show that specific mu opioid receptor transcripts are present in lung carcinoma and other cells with the mu 3 profile. Our findings identify a unique role for the mu 3 opiate receptor in opiate-mediated NO release and suggest that endogenous opiates, through their release of NO, may play a role in cancer progression.
μ3 Opiate receptor expression in lung and lung carcinoma: ligand binding and coupling to nitric oxide release / C., Fimiani; E., Arcuri; Santoni, Angela; C. M., Rialas; T. V., Bilfinger; D., Peter; B., Salzet; G. B., Stefano. - In: CANCER LETTERS. - ISSN 0304-3835. - STAMPA. - 146:(1999), pp. 45-51. [10.1016/S0304-3835(99)00227-X]
μ3 Opiate receptor expression in lung and lung carcinoma: ligand binding and coupling to nitric oxide release
SANTONI, Angela;
1999
Abstract
The mu 3 opiate receptor subtype is expressed in human surgical specimens of both normal lung and non-small-cell lung carcinoma. Nitric oxide (NO) release is mediated through the mu 3 receptor, and in lung carcinoma, morphine-stimulated NO release is significantly higher and prolonged than in normal lung. Using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis we show that specific mu opioid receptor transcripts are present in lung carcinoma and other cells with the mu 3 profile. Our findings identify a unique role for the mu 3 opiate receptor in opiate-mediated NO release and suggest that endogenous opiates, through their release of NO, may play a role in cancer progression.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.